Skip to main content
. 2016 Jan 13;7(6):7280–7296. doi: 10.18632/oncotarget.6906

Figure 2. The KRAS(G12D) mutation regulates the expression of CXCR2 and its ligands in human pancreatic cancer cells.

Figure 2

Expression levels of hCXCL1, 5 and 8 in culture supernatants of A. HPNE and HPNE-KRAS B. E6-E7-st and E6-E7-st-KRAS cells, as detected by ELISA. Values are normalized to total μg of protein. C. PCR to detect the RNA transcript levels of CXCR2 in HPNE, HPNE-KRAS and E6-E7-st, E6-E7-st-KRAS cells. D. Immunofluorescence for hCXCR2 in HPNE, HPNE-KRAS and E6-E7-st, E6-E7-st-KRAS cells. Western blots to detect the protein levels of hCXCR2 in whole cell lysates of E. HPNE, HPNE-KRAS and F. E6-E7-st, E6-E7-st-KRAS. G. ELISA to detect the levels of hCXCL1, 5 and 8 proteins in the culture supernatants of CD18/HPAF scram and CD18/HPAF-shKRAS cells. H. Western blots to detect CXCR2 protein levels in CD18/HPAF-scram and CD18/HPAF-shKRAS cells. Statistical significance determined by Student's t-test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, NS p > 0.05)